Concepedia

Author

Paweł Buszman

Medical University of SilesiaORCID

Also Known As

Aleksander Zurakowski, Andrzej Bochenek, Barbara Wiernek, Diego Ardissino, Greg L. Kaluza, Juan F. Granada, Krzysztof Milewski, Krzysztof P. Milewski, P BUSZMAN, P Buszman

323

Publications

11.3K

Citations

44

H-Index

67

Concepts

All Affiliations

Medical University of SilesiaAmerican Heart of PolandErasmus University RotterdamCardialysis (Netherlands)University Hospital of Bern
PB

About

Paweł Buszman is an author at Medical University of Silesia specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

28

38

4.7K

2

Engineering

3

3

243

3

Health Sciences

3

3

177

4

Management

2

2

231

5

Nursing

1

1

12

Paweł Buszman

×

96

Publications

10.7K

Citations

43

H-Index

YearCitations

Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease

Gregg W. Stone, Joseph F. Sabik, Patrick W. Serruys,

New England Journal of Medicine

2016

1K

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx, Marco Valgimigli, Peter Jüni,

The Lancet

2018

761

Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease

Gregg W. Stone, A. Pieter Kappetein, Joseph F. Sabik,

New England Journal of Medicine

2019

754

Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents

Patrick W. Serruys, Sigmund Silber, Scot Garg,

New England Journal of Medicine

2010

656

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial

Stephan Windecker, Patrick W. Serruys, Simon Wandel,

The Lancet

2008

650

Effects of the Direct Lipoprotein-Associated Phospholipase A <sub>2</sub> Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

Patrick W. Serruys, Héctor M. García‐García, Paweł Buszman,

Circulation

2008

503

Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial

Michał Tendera, Wojciech Wojakowski, Witold Rużyłło,

European Heart Journal

2009

464

Acute and Late Outcomes of Unprotected Left Main Stenting in Comparison With Surgical Revascularization

Paweł Buszman, Stefan Kiesz, Andrzej Bochenek,

Journal of the American College of Cardiology

2008

397

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial

Giulio Stefanini, Bindu Kalesan, Patrick W. Serruys,

The Lancet

2011

350

Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease

Patrick W. Serruys, Vasim Farooq, Bindu Kalesan,

JACC: Cardiovascular Interventions

2013

328

Page 1